|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-0.94/-1.94
|
企業價值
2.92B
|
資產負債 |
每股賬面淨值
10.21
|
現金流量 |
現金流量率
--
|
損益表 |
收益
330.53M
|
每股收益
2.39
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/05/21 19:58 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brainpenetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. |